Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.55, $0.21 better than the analyst estimate of $0.34. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $22.36 million.

“Our third quarter sales and profits were driven by strength in end-user demand, which together with continuing pipeline progress, provides a robust foundation for future growth,” stated Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “Our viscosupplementation portfolio, anchored by ORTHOVISC® and MONOVISC®, continues to grow and is poised to take and hold greater leadership in the market. We believe this strong positioning, along with our steady pipeline progress during the quarter, sets our company up to deliver financial results and shareholder value for the long term.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.